Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

DXR vs MMM: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

MMM Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 5–5 Matrix Metrics)

MMM Overall Winner 6-Pillar Tally: DXR 1 – 5 MMM Matrix Metrics: DXR 5 – 5 MMM

As of Nov 16, 2026, 3M Company (MMM) is the stronger overall head-to-head candidate over Daxor Corporation (DXR) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). DXR carries a Unified Composite Score of 52.2/100 (HOLD) at $8.36 (64.5x Forward P/E, -5894.3% operating margin), whereas MMM carries 48.9/100 (HOLD) at $181.68 (18.3x Forward P/E, 20.1% operating margin).

  • Composite vs. Pillar Nuance: While DXR currently prints a higher short-term Unified Composite Score (52.2/100 HOLD vs. MMM 48.9/100 HOLD), MMM captures the overall institutional head-to-head verdict (5–5 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (20.1% vs. -5894.3% operating margin) and revenue trajectory (+1.0% vs. +25.5% YoY).
  • Technical & Structure Timing Caution: DXR is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.2); meanwhile MMM trades in a Markup technical trend (CONSOLIDATION options phase, RSI 54.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About DXR vs MMM
DXR NASDAQ
Daxor Corporation Common Stock
Surgical & Medical Instruments & Apparatus
$8.36
-1.47% 1D
Market Cap $49.5M
TTM Revenue $31,360
Forward P/E 64.5x
Beta / 30D Vol 0.28β · 32% Vol
Unified Composite Score
52.2 / 100 HOLD
Tech 52.0 Fund 59.0 Flow 50.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -5.2%), weak momentum, RSI 31
RSI-14: 31.2 · SMA20: $8.91 · SMA50: $10.07
MMM NYSE Head-to-Head Winner
3M Company
Surgical & Medical Instruments & Apparatus
$181.68
-1.08% 1D
Market Cap $94.9B
TTM Revenue $25.2B
Forward P/E 18.3x
Beta / 30D Vol 0.74β · 45% Vol
Unified Composite Score
48.9 / 100 HOLD
Tech 33.0 Fund 48.0 Flow 72.0 Mom 41.1
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (0.6% over 20 days), RSI 54
RSI-14: 54.1 · SMA20: $180.24 · SMA50: $170.92

6-Pillar Scorecard Institutional Category Breakdown (DXR 1 – 5 MMM)

Columns: Metric · DXR · MMM
1. Valuation Multiples MMM
Forward P/E 64.5x 18.3x
Trailing P/E 7.7x 27.4x
PEG Ratio N/M 1.59x
EV / Revenue N/M 4.2x
2. Growth & Scale DXR
Revenue Growth (YoY) +25.5% +1.0%
Earnings Growth (YoY) +329.3% +69.7%
TTM Revenue (USD) $31,360 $25.2B
Market Cap $49.5M $94.9B
3. Profitability & Quality MMM
Gross Margin 100.0% 39.5%
Operating Margin -5894.3% 20.1%
Net Profit Margin 19861.4% 14.0%
Return on Equity (ROE) 14.2% 73.0%
4. Balance Sheet & Cash Flow MMM
Cash Generation (TTM) N/A $2.68B
Cash Flow Margin N/A 10.6%
Net Cash / Leverage $8.88 Book/Sh · 14.2% ROE $10.2B Net Debt (3.63x D/E)
Dividend Yield None (0.00%) 1.66%
5. Options & Positioning MMM
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile N/A (N/A) 24.5% (34th %ile)
Put/Call OI Skew N/A 0.32x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown DISTRIBUTION · Markup
6. R&D & Supply-Chain Moat MMM
OpEx & R&D Intensity N/A 19.4% of Rev ($4.90B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning High-Margin Pricing Power Moat
Supply-Chain Role Medical Instruments & Supplies Operator Conglomerates Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: DXR (5) vs MMM (5)
Institutional Metric DXR MMM Criterion Row Edge
Market Capitalization
Scale
$49.5M $94.9B Larger Scale MMM
Trailing P/E Ratio
Valuation
7.7x 27.4x Lower Multiple DXR
Forward P/E Ratio
Valuation
64.5x 18.3x Lower Multiple MMM
Revenue Growth (YoY)
Growth
+25.5% +1.0% Higher Growth DXR
Operating Margin (TTM)
Profitability
-5894.3% 20.1% Higher Margin MMM
Net Profit Margin
Profitability
19861.4% 14.0% Higher Margin DXR
Return on Equity (ROE)
Capital Efficiency
14.2% 73.0% Higher ROE MMM
52-Week Range Position
Momentum
2% ($8–$15) 74% ($139–$197) Stronger Trend MMM
Beta / 30D Volatility
Risk Regime
0.28β · 32% Vol 0.74β · 45% Vol Lower Realized Risk DXR
Unified Institutional Score
Composite Signal
52.2 / 100 (HOLD) 48.9 / 100 (HOLD) Higher Composite DXR
Trailing 12M Revenue (USD)
Operating Scale
$31,360 $25.2B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
100.0% 39.5% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev 1.59x PEG · 4.2x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A ($8.88 Book/Sh · 14.2% ROE) $2.68B ($10.2B Net Debt (3.63x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon MMM +27.15 pp
DXR: -16.87% · MMM: +10.28%
3M Horizon MMM +19.13 pp
DXR: -19.66% · MMM: -0.53%
6M Horizon MMM +45.78 pp
DXR: -17.44% · MMM: +28.34%
1Y Horizon MMM +39.75 pp
DXR: -33.27% · MMM: +6.48%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on DXR vs MMM. Trailing 12-month operating profitability (DXR -5894.3% vs MMM 20.1%) and valuation multiples (DXR 64.5x vs MMM 18.3x Forward P/E) are benchmarked directly in Pillar 4 below.

DXR ADR TTM Benchmark FX-Normalized USD
TTM Revenue$31,360
Gross Margin100.0%
Op. Margin-5894.3%
ROE / Fwd P/E14.2% · 64.5x
MMM ADR TTM Benchmark FX-Normalized USD
TTM Revenue$25.2B
Gross Margin39.5%
Op. Margin20.1%
ROE / Fwd P/E73.0% · 18.3x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
DXR UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact DXR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
MMM CONSOLIDATION
78d in phase · OBV DISTRIBUTION
Current IV 24.5%
IV Percentile 34th %ile
Put/Call OI Skew 0.32x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact MMM Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
DXR Moat Profile Cyclical / Execution-Driven Positioning
Medical Instruments & Supplies Operator
Competes within the Medical Instruments & Supplies value chain with $49.5M market capitalization and -5894.3% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
MMM Moat Profile High-Margin Pricing Power Moat
Conglomerates Operator
Competes within the Conglomerates value chain with $94.9B market capitalization and 20.1% operating margin.
OpEx & R&D Reinvestment 19.4% of Rev ($4.90B)
90D Engineering Disclosures 0 Published
Mapped Supply-Chain Ecosystem (17 partners):
Dow Inc. Exxon Mobil Corporation BASF SE SABIC

Investor FAQ DXR vs MMM Key Questions & Quantitative Answers

As of Nov 16, 2026, 3M Company (MMM) is the stronger overall head-to-head candidate over Daxor Corporation (DXR) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). DXR carries a Unified Composite Score of 52.2/100 (HOLD) at $8.36 (64.5x Forward P/E, -5894.3% operating margin), whereas MMM carries 48.9/100 (HOLD) at $181.68 (18.3x Forward P/E, 20.1% operating margin). Composite vs. Pillar Nuance: While DXR currently prints a higher short-term Unified Composite Score (52.2/100 HOLD vs. MMM 48.9/100 HOLD), MMM captures the overall institutional head-to-head verdict (5–5 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (20.1% vs. -5894.3% operating margin) and revenue trajectory (+1.0% vs. +25.5% YoY). Technical & Structure Timing Caution: DXR is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.2); meanwhile MMM trades in a Markup technical trend (CONSOLIDATION options phase, RSI 54.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

DXR leads the Growth & Scale pillar: DXR posts +25.5% YoY revenue growth and +329.3% YoY earnings growth on $31,360 TTM revenue (100.0% gross margin, -5894.3% operating margin), compared with MMM at +1.0% YoY revenue growth and +69.7% YoY earnings growth on $25.2B TTM revenue (39.5% gross margin, 20.1% operating margin). On trailing 12-month operating scale, DXR generates $31,360 in USD-normalized revenue versus $25.2B for MMM. In operating R&D and SG&A reinvestment, DXR deploys N/A (0 90-day corporate R&D disclosures) versus 19.4% of Rev ($4.90B) (0 disclosures) for MMM.

MMM screens cheaper on headline valuation multiples. DXR trades at 64.5x Forward P/E, 7.7x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas MMM trades at 18.3x Forward P/E, 27.4x Trailing P/E, 1.59x PEG, and 4.2x EV/Revenue (10.6% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against DXR (14.2% ROE) versus MMM (73.0% ROE) capital efficiency.

In options market volatility and institutional positioning, DXR carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.28β · 32% Vol realized risk). By comparison, MMM carries 24.5% implied volatility (34th %ile, Balanced (25th–60th %ile)), a 0.32x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.74β · 45% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.